UA93776C2 - Комплексный коллоидно-гиперосмолярный инфузионный препарат - Google Patents
Комплексный коллоидно-гиперосмолярный инфузионный препарат Download PDFInfo
- Publication number
- UA93776C2 UA93776C2 UAA200908880A UAA200908880A UA93776C2 UA 93776 C2 UA93776 C2 UA 93776C2 UA A200908880 A UAA200908880 A UA A200908880A UA A200908880 A UAA200908880 A UA A200908880A UA 93776 C2 UA93776 C2 UA 93776C2
- Authority
- UA
- Ukraine
- Prior art keywords
- drug
- ukraine
- hydroxyethyl starch
- application
- chloride
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 238000001802 infusion Methods 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 63
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims abstract description 34
- 229940050526 hydroxyethylstarch Drugs 0.000 claims abstract description 25
- 230000000004 hemodynamic effect Effects 0.000 claims abstract description 10
- 230000000703 anti-shock Effects 0.000 claims abstract description 6
- 238000012937 correction Methods 0.000 claims abstract description 6
- 230000009471 action Effects 0.000 claims abstract description 5
- 229940079593 drug Drugs 0.000 claims description 60
- 239000000243 solution Substances 0.000 claims description 19
- 230000000694 effects Effects 0.000 claims description 18
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 10
- 239000000600 sorbitol Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- 229920002472 Starch Polymers 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 230000000144 pharmacologic effect Effects 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 4
- 230000002727 hyperosmolar Effects 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 238000001784 detoxification Methods 0.000 claims description 3
- 230000023597 hemostasis Effects 0.000 claims description 3
- 230000004060 metabolic process Effects 0.000 claims description 3
- 230000004087 circulation Effects 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 230000035987 intoxication Effects 0.000 claims description 2
- 231100000566 intoxication Toxicity 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 2
- 244000309464 bull Species 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims 3
- 241000700159 Rattus Species 0.000 claims 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
- 238000002474 experimental method Methods 0.000 claims 2
- 239000000463 material Substances 0.000 claims 2
- 231100000915 pathological change Toxicity 0.000 claims 2
- 230000036285 pathological change Effects 0.000 claims 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 claims 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 1
- 201000003126 Anuria Diseases 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 206010010071 Coma Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 206010020660 Hyperlactacidaemia Diseases 0.000 claims 1
- 208000005018 Hyperlactatemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020919 Hypervolaemia Diseases 0.000 claims 1
- 206010051125 Hypofibrinogenaemia Diseases 0.000 claims 1
- 241000867418 Morion Species 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 206010030302 Oliguria Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 230000007059 acute toxicity Effects 0.000 claims 1
- 231100000403 acute toxicity Toxicity 0.000 claims 1
- 238000010171 animal model Methods 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 239000003633 blood substitute Substances 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000001186 cumulative effect Effects 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 235000011187 glycerol Nutrition 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 231100000636 lethal dose Toxicity 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 238000011160 research Methods 0.000 claims 1
- 235000002020 sage Nutrition 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 210000001835 viscera Anatomy 0.000 claims 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 abstract description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 18
- 239000001540 sodium lactate Substances 0.000 abstract description 16
- 229940005581 sodium lactate Drugs 0.000 abstract description 16
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 abstract description 15
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 abstract description 15
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 abstract description 15
- 235000011088 sodium lactate Nutrition 0.000 abstract description 15
- 239000000811 xylitol Substances 0.000 abstract description 15
- 235000010447 xylitol Nutrition 0.000 abstract description 15
- 229960002675 xylitol Drugs 0.000 abstract description 15
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 abstract description 14
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 abstract description 14
- 239000011780 sodium chloride Substances 0.000 abstract description 10
- 239000001103 potassium chloride Substances 0.000 abstract description 9
- 235000011164 potassium chloride Nutrition 0.000 abstract description 9
- 239000001110 calcium chloride Substances 0.000 abstract description 8
- 229910001628 calcium chloride Inorganic materials 0.000 abstract description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 abstract description 7
- 229910001629 magnesium chloride Inorganic materials 0.000 abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 6
- 239000003795 chemical substances by application Substances 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 14
- 239000000203 mixture Substances 0.000 description 11
- 239000011575 calcium Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- 230000003113 alkalizing effect Effects 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 208000010444 Acidosis Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 229930091371 Fructose Natural products 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000001632 sodium acetate Substances 0.000 description 3
- 235000017281 sodium acetate Nutrition 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- ZKNSZZXBPSICFK-UHFFFAOYSA-N 2,2-bis(4-chlorophenoxy)acetic acid Chemical compound C=1C=C(Cl)C=CC=1OC(C(=O)O)OC1=CC=C(Cl)C=C1 ZKNSZZXBPSICFK-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 206010059484 Haemodilution Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 206010027417 Metabolic acidosis Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 229940027278 hetastarch Drugs 0.000 description 2
- -1 hydroxyethyl alcohol Chemical compound 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940001447 lactate Drugs 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000009965 odorless effect Effects 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001183 volemic effect Effects 0.000 description 2
- SZIFAVKTNFCBPC-UHFFFAOYSA-N 2-chloroethanol Chemical class OCCCl SZIFAVKTNFCBPC-UHFFFAOYSA-N 0.000 description 1
- 101100313371 African swine fever virus (isolate Tick/Malawi/Lil 20-1/1983) Mal-130 gene Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 241000566113 Branta sandvicensis Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010072104 Fructose intolerance Diseases 0.000 description 1
- 102000027487 Fructose-Bisphosphatase Human genes 0.000 description 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019878 Hereditary fructose intolerance Diseases 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 229920002123 Pentastarch Polymers 0.000 description 1
- 239000008156 Ringer's lactate solution Substances 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000007950 acidosis Effects 0.000 description 1
- 208000026545 acidosis disease Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 231100000567 intoxicating Toxicity 0.000 description 1
- 230000002673 intoxicating effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000003893 lactate salts Chemical group 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000000051 modifying effect Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940101738 pentastarch Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003058 plasma substitute Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011110 re-filtration Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000287 tissue oxygenation Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940075601 voluven Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA200908880A UA93776C2 (ru) | 2009-08-25 | 2009-08-25 | Комплексный коллоидно-гиперосмолярный инфузионный препарат |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA200908880A UA93776C2 (ru) | 2009-08-25 | 2009-08-25 | Комплексный коллоидно-гиперосмолярный инфузионный препарат |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA93776C2 true UA93776C2 (ru) | 2011-03-10 |
Family
ID=50831119
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200908880A UA93776C2 (ru) | 2009-08-25 | 2009-08-25 | Комплексный коллоидно-гиперосмолярный инфузионный препарат |
Country Status (1)
| Country | Link |
|---|---|
| UA (1) | UA93776C2 (ru) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2732754C1 (ru) * | 2020-06-01 | 2020-09-22 | Совместное предприятие в форме общества с ограниченной ответственностью «РЕМЕДИ ГРУП» | Способ изготовления комплексного инфузионного препарата и его применение для коррекции гиперфосфатемии и уменьшения сосудистой непроницаемости у больных с почечной недостаточностью |
| WO2021229467A1 (en) * | 2020-05-12 | 2021-11-18 | M.T.K. Medical Center Limited Liability Company | Combined hyperosmolar solution for infusion |
-
2009
- 2009-08-25 UA UAA200908880A patent/UA93776C2/ru unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021229467A1 (en) * | 2020-05-12 | 2021-11-18 | M.T.K. Medical Center Limited Liability Company | Combined hyperosmolar solution for infusion |
| RU2732754C1 (ru) * | 2020-06-01 | 2020-09-22 | Совместное предприятие в форме общества с ограниченной ответственностью «РЕМЕДИ ГРУП» | Способ изготовления комплексного инфузионного препарата и его применение для коррекции гиперфосфатемии и уменьшения сосудистой непроницаемости у больных с почечной недостаточностью |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI326597B (en) | Bicarbonate-based solutions for dialysis therapies | |
| Locatelli et al. | Optimizing haemodialysate composition | |
| KR20050089833A (ko) | 이코덱스트린을 함유하는 생체친화성 투석액 | |
| JP4870944B2 (ja) | 眼薬用組成物 | |
| Simoni et al. | Artificial Oxygen Carrier With Pharmacologic Actions of Adenosine‐5′‐Triphosphate, Adenosine, and Reduced Glutathione Formulated to Treat an Array of Medical Conditions | |
| MXPA04012299A (es) | Una solucion estable a base de bicarbonato en un recipiente individual. | |
| UA93776C2 (ru) | Комплексный коллоидно-гиперосмолярный инфузионный препарат | |
| RU2550963C2 (ru) | Адаптированный к плазме сбалансированный раствор электролитов | |
| CN106309481A (zh) | 复方门冬氨酸钾葡萄糖注射液及其制备方法 | |
| Miles et al. | Dialytic therapy for diabetic patients with terminal renal failure | |
| JP4361493B2 (ja) | 腹膜透析用薬剤の製造のための医学的溶液を調製する方法 | |
| MULLER et al. | Metabolic effects of plasma expanders | |
| UA123110C2 (uk) | Комплексний білково-сольовий гіперосмолярний інфузійний розчин | |
| JP4361492B2 (ja) | 腹膜透析用薬剤の製造のための医学的溶液を調製する方法 | |
| KR20060128972A (ko) | 적혈구 기능 수식 물질 | |
| RU2425684C1 (ru) | Способ получения диализирующей жидкости | |
| EP4149428B1 (en) | Combined hyperosmolar solution for infusion | |
| JPH0469341A (ja) | Ｔｐｎ用糖電解質液 | |
| RU2185173C2 (ru) | Препарат гемодинамического действия с функцией нормализации кислотно-основного равновесия и электролитного баланса | |
| UA93139C2 (ru) | Сложный комплексный гиперосмолярный инфузионный препарат | |
| ES2307655T3 (es) | Liquido para hemofiltracion. | |
| RU2289395C2 (ru) | Способ лечения тяжелой компрессионной травмы мягких тканей | |
| Daha et al. | A rationale approach to perioperative fluid therapy in adult patients | |
| RU2224504C1 (ru) | Способ получения раствора "хлосоль" | |
| UA145370U (uk) | Кристалоїдний інфузійний розчин |